- Home
- PRAX vs AUTL Comparison
PRAX vs AUTL Comparison
Compare PRAX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- AUTL
- Stock Information
- Founded
- PRAX 2015
- AUTL 2014
- Country
- PRAX United States
- AUTL United Kingdom
- Employees
- PRAX N/A
- AUTL N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRAX Health Care
- AUTL Health Care
- Exchange
- PRAX Nasdaq
- AUTL Nasdaq
- Market Cap
- PRAX 1.2B
- AUTL 1.1B
- IPO Year
- PRAX 2020
- AUTL 2018
- Fundamental
- Price
- PRAX $71.76
- AUTL $3.08
- Analyst Decision
- PRAX Strong Buy
- AUTL Strong Buy
- Analyst Count
- PRAX 9
- AUTL 2
- Target Price
- PRAX $146.33
- AUTL $11.50
- AVG Volume (30 Days)
- PRAX 317.5K
- AUTL 2.3M
- Earning Date
- PRAX 11-06-2024
- AUTL 11-12-2024
- Dividend Yield
- PRAX N/A
- AUTL N/A
- EPS Growth
- PRAX N/A
- AUTL N/A
- EPS
- PRAX N/A
- AUTL N/A
- Revenue
- PRAX $1,605,000.00
- AUTL $10,091,000.00
- Revenue This Year
- PRAX N/A
- AUTL $816.67
- Revenue Next Year
- PRAX N/A
- AUTL $374.47
- P/E Ratio
- PRAX N/A
- AUTL N/A
- Revenue Growth
- PRAX N/A
- AUTL 82.71
- 52 Week Low
- PRAX $14.25
- AUTL $2.94
- 52 Week High
- PRAX $86.93
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- PRAX 48.78
- AUTL 35.72
- Support Level
- PRAX $58.84
- AUTL $3.24
- Resistance Level
- PRAX $86.93
- AUTL $4.12
- Average True Range (ATR)
- PRAX 6.09
- AUTL 0.37
- MACD
- PRAX -0.15
- AUTL -0.09
- Stochastic Oscillator
- PRAX 46.00
- AUTL 8.48
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.